MCM
AGIO icon

Mazama Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Mazama Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-760
Closed -$21K – 248
2013
Q3 		$21K Buy
+760
New +$21K 0.01% 209

Other funds holding AGIO

TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Mazama Capital Management's AGIO Position: Q4 2013 in Review

Mazama Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2013, closing a stake of 760 shares — an estimated $21K sold.

Mazama Capital Management first reported a position in AGIO in Q3 2013 and held it in 1 quarter. The position peaked at $21K in Q3 2013. 66 funds tracked by Wall St. Rank hold AGIO as of Q4 2013.

  • Mazama Capital Management reported no remaining Agios Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Mazama Capital Management sold 760 Agios Pharmaceuticals shares in Q4 2013, an estimated $21K.
  • Mazama Capital Management first reported a position in Agios Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Mazama Capital Management's Agios Pharmaceuticals position peaked at $21K in Q3 2013.
  • 66 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2013.

Based on Mazama Capital Management's 13F filing for Q4 2013, filed 10 Feb 2014.